TuHURA Biosciences (NASDAQ:HURA - Free Report) - Research analysts at Zacks Small Cap dropped their Q3 2025 earnings estimates for shares of TuHURA Biosciences in a research report issued on Monday, May 19th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will earn ($0.17) per share for the quarter, down from their previous estimate of ($0.15). Zacks Small Cap also issued estimates for TuHURA Biosciences' Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.63) EPS and FY2026 earnings at ($0.65) EPS.
TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02).
Separately, HC Wainwright restated a "buy" rating and issued a $12.00 price target on shares of TuHURA Biosciences in a research note on Friday, May 16th.
Check Out Our Latest Stock Report on HURA
TuHURA Biosciences Trading Down 11.0%
Shares of HURA opened at $3.31 on Thursday. The firm has a fifty day simple moving average of $3.77 and a two-hundred day simple moving average of $4.06. TuHURA Biosciences has a 1-year low of $1.80 and a 1-year high of $7.93.
Hedge Funds Weigh In On TuHURA Biosciences
Institutional investors have recently made changes to their positions in the business. Apollon Wealth Management LLC purchased a new stake in TuHURA Biosciences during the fourth quarter valued at approximately $253,000. Charles Schwab Investment Management Inc. purchased a new position in shares of TuHURA Biosciences during the 4th quarter worth $61,000. Geode Capital Management LLC bought a new stake in shares of TuHURA Biosciences during the 4th quarter valued at $1,084,000. Suncoast Equity Management purchased a new stake in shares of TuHURA Biosciences in the 4th quarter worth $421,000. Finally, TT Capital Management LLC bought a new position in TuHURA Biosciences in the 4th quarter worth $41,000. Institutional investors own 0.62% of the company's stock.
TuHURA Biosciences Company Profile
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
